Since imatinib was the first TKI targeting BCR-ABL in the treatment of CML, the imatinib-resistant CML K562 cell line was established in our laboratory for experiments. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.